Patients with bullous pemphigoid treated with Dupixent maintained disease control and symptom relief, according to phase 2/3 trial results released by Regeneron and Sanofi.
The randomized, double-blind, placebo-controlled ADEPT trial included 106 adult patients with moderate to severe bullous pemphigoid who were randomly assigned to receive Dupixent (dupilumab) or placebo every 2 weeks with oral corticosteroids (OCS) for a total of 52 weeks.
Sustained disease remission, defined as complete clinical remission with completion of OCS without relapse or rescue therapy use, was achieved by 20% of